Literature DB >> 32895174

[Inhibitory effect of Biejiajian pills against diethylnitrosamine-induced hepatocarcinogenesis in rats].

Minghui Feng1, Songqi He2, Songze Huang2, Jiaxin Lin2, Huilin Yang2, Jiaji Wang2, Jie Pang2.   

Abstract

OBJECTIVE: To study the inhibitory effect of Biejiajian pills (BJJ) agaisnt diethylnitrosamine (DEN)-induced hepatocarcinogenesis and explore the relation between this effect and the inflammasome signaling pathway.
METHODS: Sixty-five male SD rats were randomly divided into control group, DEN model group, and 3 BJJ treatment groups at low, medium and high dose (with daily dose of 0.55, 1.1 and 2.2 g/kg, respectively, for 12 consecutive weeks starting from the 5th week after modeling). The pathological changes of the liver tissue were observed with HE and Masson staining, and serum levels of alanine transaminase (ALT), glutamic oxaloacetic transaminase (AST), alkaline phosphatase (ALP) and total bilirubin (TBIL) of the rats were detected using ELISA. Oxidation stress in the liver tissue was assessed with ELISA, and Western blotting and ELISA were used to detect the molecular expressions of inflammasome-related pathway.
RESULTS: BJJ significantly inhibited tumor growth in the liver of the rats. HE and Masson staining showed that BJJ treatment obviously ameliorated liver fibrosis and reduced cancer cell and inflammatory cell infiltration in the liver. BJJ significantly reduced elevations of serum ALT, AST, ALP and TBIL levels, increased the contents of superoxide dismutase, catalase and glutathione peroxidase in the liver and suppressed malondialdehyde in Den-treated rats. BJJ also dose-dependently decreased the expressions of NLRP3, apoptosis-associated speck-like protein (ASC), caspase-1, pro-IL-1β, pro-IL-18, IL-1β and IL-18 in the liver of Den-treated rats.
CONCLUSIONS: BJJ treatment can dose-dependently inhibit DEN-induced hepatocarcinogenesis by enhancing antioxidant capacity and down-regulating inflammatory-related pathways in rats.

Entities:  

Keywords:  Biejiajian pills; NLRP3; diethylnitrosamine; hepatocellular carcinoma; inflammasomes

Mesh:

Substances:

Year:  2020        PMID: 32895174      PMCID: PMC7429160          DOI: 10.12122/j.issn.1673-4254.2020.08.12

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  14 in total

Review 1.  Heated moxibustion and bloodletting in Tibetan medical literature of Dunhuang Heritage.

Authors:  Qi Zhao; Mo-Zheng Wu; Ji-Ping Zhao
Journal:  Chin J Integr Med       Date:  2012-04-02       Impact factor: 1.978

2.  Introduction: The burden of hepatocellular carcinoma.

Authors:  Leonard B Seeff
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

3.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

4.  [Adenovirus-mediated transfer of anti-MDR1 ribozyme in the treatment of multidrug-resistant human lymphoma in SCID mice].

Authors:  Dongping Xu; Fusheng Wang; Takao Ohnuma; Lei Jin
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2002-11

5.  Cancer statistics: updated cancer burden in China.

Authors:  Wanqing Chen
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

6.  The role of liver transplantation or resection for patients with early hepatocellular carcinoma.

Authors:  Kuan-Chun Hsueh; Ting-Ying Lee; Chew-Teng Kor; Tsung-Ming Chen; Tzu-Ming Chang; Shun-Fa Yang; Chung-Bao Hsieh
Journal:  Tumour Biol       Date:  2015-10-22

7.  Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis.

Authors:  Sameh Saber; Amal M H Ghanim; Eman El-Ahwany; Eman M Abd El-Kader
Journal:  Cancer Chemother Pharmacol       Date:  2020-01-27       Impact factor: 3.333

Review 8.  Inflammasomes: current understanding and open questions.

Authors:  Franz Bauernfeind; Andrea Ablasser; Eva Bartok; Sarah Kim; Jonathan Schmid-Burgk; Taner Cavlar; Veit Hornung
Journal:  Cell Mol Life Sci       Date:  2010-10-31       Impact factor: 9.207

Review 9.  NALP inflammasomes: a central role in innate immunity.

Authors:  Fabio Martinon; Olivier Gaide; Virgine Pétrilli; Annick Mayor; Jürg Tschopp
Journal:  Semin Immunopathol       Date:  2007-08-17       Impact factor: 11.759

Review 10.  Role of the NLRP3 inflammasome in cancer.

Authors:  Maryam Moossavi; Negin Parsamanesh; Afsane Bahrami; Stephen L Atkin; Amirhossein Sahebkar
Journal:  Mol Cancer       Date:  2018-11-17       Impact factor: 27.401

View more
  1 in total

Review 1.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.

Authors:  Stavros P Papadakos; Nikolaos Dedes; Elias Kouroumalis; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.